Lapatinib Stada Arzneimittel Ag

Lapatinib, the active ingredient in Lapatinib Stada Arzneimittel Ag, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats HER2‑positive breast cancer in adult patients. It is indicated for patients with advanced or metastatic disease and is often used in combination with other anticancer agents.

GNH USA supplies Lapatinib Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Lapatinib is used to target HER2‑driven breast cancer pathways. - HER2‑positive breast cancer: Used in combination with chemotherapy to inhibit tumor growth in patients with advanced disease. - Metastatic HER2‑positive breast cancer: Provides disease control when other HER2‑targeted therapies have failed. - HER2‑positive breast cancer after trastuzumab: Offers an oral alternative to continue HER2 blockade in patients progressing on prior therapy.

Lapatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent watery stools. - Rash: skin eruptions. - Nausea: feeling of sickness.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac dysfunction: reduced left ventricular ejection fraction. - Stevens‑Johnson syndrome: severe skin reaction with blistering.

When prescribing Lapatinib, clinicians should observe several precautionary measures to minimize risk. - Cardiac monitoring: assess baseline and periodic left ventricular function. - Liver function tests: monitor transaminases before and during therapy. - QT interval: obtain ECG and correct electrolyte abnormalities. - Drug interactions: avoid strong CYP3A4 inhibitors and adjust dose if necessary. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with patient. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Lapatinib interacts with several medicines; awareness of these interactions helps maintain efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Lapatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Digoxin: possible increase in serum concentration, check levels. - Statins metabolized by CYP3A4 (e.g., simvastatin): risk of myopathy, consider dose adjustment.